Physicians Lack Feedback on Accuracy of Diagnoses
Clinical diagnosis is a largely open-loop system in which there is no systematic way for clinicians to obtain feedback on the outcome of their diagnoses, according to an article published in a supplement to the May issue of The American Journal of Medicine.
TUESDAY, April 29 (HealthDay News) -- Clinical diagnosis is a largely open-loop system in which there is no systematic way for clinicians to obtain feedback on the outcome of their diagnoses, according to an article published in a supplement to the May issue of The American Journal of Medicine.
Gordon D. Schiff, M.D., of Brigham and Women's Hospital in Boston, examines the numerous barriers to feedback and follow-up in the current system of medical diagnosis, such as the lack of a system for doctors to get feedback, the reluctance of physicians to receive and offer criticism, the discontinuousnature of patient care, and reliance on patient return for follow-up. The barriers imposed by the system of managed care also discourage feedback, the author notes.
Acknowledging that diagnosis is not a label, but an intrinsic part of the physician-patient relationship, is an important aspect of establishing a mechanism for feedback, the author explains, as the patient should be seen as a partner in the process of testing the diagnostic hypothesis.
"Learning and feedback are inseparable. The old tools -- ad hoc fortuitous feedback, individual idiosyncratic systems to track patients, reliance on human memory and patient adherence to or initiating of follow-up appointments -- are too unreliable to be depended upon to ensure high quality in modern diagnosis," the author writes.
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.
